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http://dx.doi.org/10.1016/j.asjsur.20Summary Objectives: Thymomas are relatively rare tumors. In this study, we investigated
the clinical features of patients who underwent surgical resection for thymoma.
Patients and methods: This study clinicopathologically evaluated 54 consecutive patients who
underwent a surgical resection of thymoma in our department between 1994 and 2006.
Results: A complete resection was performed in 52 patients, while two patients underwent an
incomplete resection due to pleural dissemination. Combined resection with adjacent organs
was performed for the lung (nZ 6), pericardium (nZ 5), and large vessels (brachiocephalic
vein in three, superior vena cava in two). The concomitant autoimmune diseases were
observed in 20 patients (37%), and they included myasthenia gravis in 17 patients, macroglob-
ulinemia in one, pemphigus vulgaris in one, and stiff person syndrome in one patient. The
histologic types of the World Health Organization classification diagnosed as type A in four
patients, type AB in 14, type B1 in eight, type B2 in 15, and type B3 in 11. There were 27,
17, eight, and two patients with Masaoka stages I, II, III, and IV, respectively. Four patients
died, and the causes of death included recurrence of thymoma in two, gastric carcinoma in
one, and respiratory failure due to myasthenia gravis in one patient. The overall survival rate
at 10 years was 94.6% in patients with stages I and II disease and 77.1% in patients with stages
III and IV disease.Department of Surgery, University of Occupational and Environmental Health, School of Medicine, 1-1
807-8555, Japan.
h-u.ac.jp (T. Hanagiri).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
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Surgical resection of thymoma 145Conclusions: Long-term survival can be expected not only for patients at early stages, as well
as for patients with stages III and IV disease if surgical resection is completed macroscopically.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Thymoma is a relatively rare tumor, with an incidence of
0.15 cases per 100,000. The neoplasm arises from thymic
epithelial cells.1 The site of predilection for thymoma is
usually in the thymus at the anterior mediastinum. This
location accounts for 20%e40% of mediastinal tumors and is
the most common tumor in the anterior mediastinum.2,3 It
is normally a slow-growing tumor, but it shows a locally
invasive growth pattern. In addition, it sometimes leads to
the development of pleural dissemination and distant
metastasis.4 Surgery is the treatment of choice for this
disease, and complete resection is the most important
prognostic factor.4,5,6 The staging of thymomas is
commonly performed based on the Masaoka classification,
and the clinical staging also predicts the prognosis.7
However, no optimal treatment strategy has yet been
established. In this study, we retrospectively reviewed the
clinicopathologic characteristics of 54 consecutive patients
who underwent surgical resection for thymoma.Table 1 Characteristics of the thymoma patients with/
without MG.
All Without MG
nZ 37
With MG
nZ 17
Average of age,
y (range)
60.5 (19e76) 63.1 54.1*
Sex: male/female 26/28 19/18 7/10
WHO histologic classification
A 4 3 (9) 1 (6)
AB 14 10 (29) 4 (24)
B1 8 6 (17) 2 (12)
B2 15 7 (20) 8 (53)**
B3 11 9 (26) 2 (12)
Masaoka stage
I 27 17 (46) 10 (59)
II 17 12 (32) 5 (29)
III 8 6 (16) 2 (12)
IVa 2 2 (5) 02. Patients and methods
The hospital records of 54 consecutive patients who under-
went a surgical resection of thymoma in the Second
Department of Surgery, University of Occupational and
Environmental Health (Kiatkyushu, Japan) between 1994and
2006were reviewed. The preoperative assessments included
chest roentgenography and computed tomography (CT) of
the chest, upper abdomen, and brain. Patient records,
including clinical data, preoperative examination results,
details of any surgeries, histopathologic findings, and
Masaoka staging system classification were also reviewed.7
The histologic findings were classified according to the
World Health Organization (WHO) criteria of cell types.8
Follow-up information was obtained from all patients
through office visits or telephone interviews, either with the
patients,witha relative,orwith theirprimaryphysicians.The
patients were evaluated every 3 months by chest roentgen-
ography, and chest CT scans were performed every 6 months
for the first 2 years after surgery and annually thereafter.
The Kaplan-Meier method was used to estimate the prob-
ability of survival, and survival differences were analyzed by
the log-rank test. The categorical variables were compared
using the chi-square test or Fisher’s exact test. Differences
were considered to be statistically significant for p< 0.05.
The data were analyzed using the StatView software package
(Abacus Concepts, Inc., Berkeley, CA, USA).MGZmyasthenia gravis.
*pZ 0.019, the average age of patients with MG was signifi-
cantly lower than that of patients without MG.
**pZ 0.043, the prevalence of MG was observed significantly in
type B2 thymoma compared with that in other types of thy-
moma.3. Results
There were 26 men and 28 women studied who had a mean
age of 60.5 years and an age range of 19e79 years (Table 1).Fifty-two patients underwent complete resection, and two
patients had pleural dissemination that resulted in an
incomplete resection. Among the patients who underwent
a complete resection, combined resection with adjacent
organs was performed for the lung (nZ 6), pericardium
(nZ 5), and vessels (brachiocephalic vein in three, superior
vena cava in two). The histologic types based on the WHO
classification included four patients with type A (7.7%), 14
with type AB (26.9%), eight with type B1 (15.4%), 15 with
type B2 (28.8%), and 11 with type B3 (21.1%). The histologic
types of two patients were not determined because the
subjects had received preoperative radiation. In the
Masaoka staging system, 27 patients (50.0%) were diag-
nosed to have stage I disease, 17 with stage II (31.5%), eight
with stage III (14.8%), and two with stage IVa (3.7%). The
youngest patients (a woman aged 19 years) was diagnosed
at Masaoka stage III, and a complete resection was per-
formed with combined resection of brachiocephalic vein.
The correlation between Masaoka stage and WHO clas-
sification was revealed in Table 2. The patients with
Masaoka stage I and II was classified into one of the five
histologic types of WHO classification. However, the thy-
momas at Masaoka stage III and IVa corresponded to either
B2 or B3 subtype, indicating more aggressive histology. The
higher prevalence of early stages (Masaoka stages I and II)
was observed in A and AB-type thymomas (18/18), while
the proportion of Masaoka stages I and II was 76.5 % (26/34)
Table 2 Correlation between Masaoka stage and WHO
histologic classification.
WHO histologic
classification
A AB B1 B2 B3
Masaoka stage
I (nZ 27) 3 9 5 8 2
II (nZ 17) 1 5 3 6 2
III (nZ 6) 0 0 0 1 5
IV (nZ 2) 0 0 0 0 2
WHOZWorld Health Organization.
%
100
146 S. Shinohara et al.in B1 through B3 thymomas (pZ 0.039). The correlation
between tumor size and Masaoka stage is indicated in
Fig. 1A. The average tumor size in Masaoka stage I was
significantly smaller than that in Masaoka stages IIIeIV. No
significant correlation was observed between tumor size
and WHO histologic classification (Fig. 1B). The concomi-
tant autoimmune diseases were myasthenia gravis (MG) in
17 patients, macroglobulinemia in one, pemphigus vulgaris
in one, and stiff person syndrome in one. In comparison
between presence and absence of MG, the average age of
patients with MG was significantly lower than that of
patients without MG. In particular, four out of five patients
younger than 40 years of age were diagnosed in association
with MG. The prevalence of MG was significantly higher in
type B2 thymoma than those in other types of thymoma.
There was no postoperative mortality, and no morbidity.
Radiation therapy was performed before surgery in four
patients (one patient with stage I, three with stage III).
Postoperative radiation therapy to the anterior medias-
tinum was performed in three patients with stage II
disease, four with stage III, and one with stage IV disease.
Two patients with stage IV and one patient with stage III
disease underwent postoperative chemotherapy with car-
boplatin plus etoposide. Four patients died, and the causes
of death included recurrence of thymoma in two, gastric
carcinoma in one, and respiratory failure due to MG in one
patient. The overall survival rate at 10 years was 94.6% in
patients with stages I and II disease. The patients withA B
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Figure 1 Tumor size according to Masaoka stage or WHO
histologic classification. (A) Correlation between tumor size
and Masaoka stage; (B) correlation between tumor size and
WHO histologic classification. The results are expressed as the
average values plus standard deviation. *pZ 0.023, the tumor
size in Masaoka stage I was significantly smaller than that in
Masaoka stages III and IV. WHOZWorld Health Organization.stages III and IV disease showed a poorer prognosis (77.1%
survival) than the patients with stages I and II disease
(pZ 0.129; Fig. 2). The overall survival rates at 10 years
were 100% in WHO type A or AB patients, 87.5% in WHO B1,
92.0% in WHO B2, and 75.0% in WHO B3 patients (Fig. 3).
The patients with type A or AB classifications showed no
recurrent disease.4. Discussion
Thymoma is largely characterized by an indolent growth
pattern and often shows very slow progression. However, it
has malignant potential and sometimes invades surrounding
structures and disseminates into the pleural cavity. The
mainstay of therapy is complete surgical resection for early
stage disease. It has been reported that complete resection
of thymoma was significantly associated with a better
prognosis.4e6 In the present study, 52 patients (96%)
underwent a complete resection, and the combined
resection of adjacent organs was performed in 16 patients
(29.6%). In the patients with disseminated pleural nodules,
we attempted to resect all of the disseminated nodules
macroscopically. In spite of its local invasiveness, lym-
phogenous and hematogenous spread of thymoma is rare.4
We experienced only one patient who developed metas-
tases in the lung, liver, and bone 15 months after surgery.
The Masaoka staging system is based on the degree of
invasion of the tumor through the capsule into the
surrounding structures, and is an important prognostic
factor to determine the optimal therapeutic method for the
patient.7,9 The patients with stages III and IV disease
showed a poorer prognosis than patients with stages I and II
disease in the present study; however, there was no
significant difference. It is thought to be due to small
number of patients in each Masaoka stage. The average
tumor size was correlated with Masaoka stage in the
present study. The histologic grade of aggressiveness is also80iv
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Figure 2 Overall survival curves after surgery according to
the Masaoka stage. The overall survival rates at 10 years were
94.6% and 77.1% in patients with stages I and II and stages III
and IV disease, respectively. The patients with stages III and IV
disease showed a poorer prognosis than patients at an earlier
stage (I and II; pZ 0.129).
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Figure 3 Overall survival curves after surgery according to
the WHO classification. The overall survival rates at 10 years
were 100% in WHO types A or AB patients, 87.5% in WHO type
B1, 92.0% in WHO type B2, and 75.0% in WHO type B3 patients.
WHOZWorld Health Organization.
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the WHO classification was created, and thymic epithelial
tumors are classified into types A, AB, B1, B2, B3, and C
(thymic carcinoma) according to the WHO criteria. The
criteria are useful for determining the treatment regimens
and predicting patient survival. The WHO classification has
a mild correlation with the Masaoka staging, indicating that
there is a trend for more malignant WHO cell types was
associated with more advanced Masaoka stages. All
patients with WHO type A or AB had a diagnosis of either
Masaoka stages I or II in the present study. However, the
patients with Masaoka stage I included WHO classifications
of types A, AB, B1, B2, and B3 in the present study. Several
studies have demonstrated a consensus that the Masaoka
staging, WHO histologic classification, and completeness of
surgical resection were significant prognostic factors.10,11
Thymomas are often associated with a number of
immune- and nonimmune-mediated paraneoplastic
syndromes. Almost 40% of patients with thymoma develop an
autoimmune-paraneoplastic syndrome.12 MG is the most
common of these syndromes. In the present study, 20
patients (37%) had parathymic autoimmune disease. The
average age of patients with MG was significantly lower than
that of patients without MG. In particular, four out of five
patients younger than 40 years of age were diagnosed in
associationwithMG. In a clinical reviewof 1089 patientswith
thymoma, Kondo et al6 reported a 25% incidence of MG.
There was no overall survival difference between patients
with or without MG. Hypogammaglobulinemia and pure red
cell aplasia have also often been reported to be concomitant
autoimmune diseases.13 Surgery alone is considered to be
curative treatment for stage I thymoma, and it results in 10-
year overall survival rates of almost 100%. However, there is
little randomized evidence to guide the treatment for stages
IIeIV disease. There is still controversy regarding the value of
postoperative prophylactic radiotherapy for patients with
stage II disease.14e16 Furthermore, late local morbidities
associated with mediastinal irradiation are well known (suchas cardiacmorbidities such as valve fibrosis, pericarditis with
pericardial effusions, increased frequencyof coronary artery
disease, radiation pneumonia, chronic pulmonary fibrosis).17
For stage III thymomas, a one-stage operation is generally
performed when a complete resection by combined resec-
tion of the lung and pericardium can be expected. Regarding
postoperative radiotherapy, several studies have reported
that it improved the prognosis or inhibited local recur-
rence.18,19 Radiotherapy may also be useful as adjuvant
therapy in cases of incomplete surgical resection with
microscopic ormacroscopic residual disease. Several reports
demonstrated the effectiveness of chemotherapy as one arm
of multidisciplinary treatment in patients with advanced
thymoma.20 However, no sufficient evidence exists regarding
the effectiveness of adjuvant chemotherapy, and there is
currently no standardized regimen for chemotherapy.
Nevertheless, chemotherapy is considered a valid option in
selected patients with residual disease after local treat-
ments, or as a neoadjuvant approach to improve the
resectability in patients with Masaoka stages III or IV-
a thymoma.21,22
The most common recurrence pattern of stage III thy-
moma is pleural dissemination, but opinions are divided as
to the clinical significance of the resection of recurrent
lesions. Hanuda et al23 indicated that reoperation was not
significantly effective for prolongation of the post-
recurrence survival for patients with recurrent thymoma.
Although pleuropneumonectomy for Masaoka stage IVa
thymoma is associated with a high morbidity and mortality
rate, pleuropneumonectomy or total resection of minimal
pleural dissemination may provide good long-term survival
in highly selected patients.24,25
The WHO classification of thymoma has correlation with
Masaoka stage, and the prevalence of MG was significantly
higher in type B2 thymoma those that in other types of
thymoma. Long-term survival can be expected not only for
patients at early stages, but also for patients with stages III
and IV disease if surgical resection is completed macro-
scopically. There have so far been only a few clinical trials
regarding adjuvant chemotherapy or radiotherapy for thy-
moma because of its low incidence. Further accumulation
of clinical experience with the disease and establishment of
an effective treatment strategy are needed for improve-
ment of the quality of life of patients because long-term
survival can be expected not only for patients with early
stage disease, but also for those with advanced disease.
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